肺癌患者端粒酶表达的meta分析

Expression of human telomerase in lung cancer: A meta-analysis of diagnostic test

目的 衡量端粒酶活性和肺癌的相关性 ,综合评价端粒酶活性作为肺癌诊断标记物的效度。方法 检索并筛选出 2 8篇有关端粒酶活性和肺癌的流行病学资料 ,用meta分析 (包括Fleiss固定效应模型或D L随机效应模型 )合并效应尺度OR ,并汇总端粒酶活性在肺癌诊断中的特异度和灵敏度 ,评价该肿瘤标记物的效度。结果 D L法计算OR合并为 66.43( 38.48～ 10 4.5 3) ;Fleiss法将同质的 2 5项研究结果加权合并后 ,肺癌组累积 1361例 ,对照组累积 132 1例 ,检测灵敏度为 0 .7987,特异度为 0 .934 1。结论 端粒酶是一种较理想的诊断性肿瘤标志物 ,该研究结果为将端粒酶活性检测纳入肺癌筛检计划提供一定的理论依据。

Objective To systematically evaluate the validity of telomerase activity as a tumor marker of lung cancer and measure the correlation of telomerase activity and lung cancer. Methods The meta-analysis combined of data from 28 selected literatures was performed to calculate the effect magnitude of combined odds ratio (OR) and fixed effect model (Flessi) or random effect model (D-L) for estimating the tumor marker's sensitivity, specificity and its validity. Results Twenty-eight studies were identified. A heterogeneity test was highly significant (P<0.05). The combined OR was 66.43 (95%CI, 38.48 to 104.53) by D-L. After exclusion of three reports, the data was homogeneous totaling 1?361 in lung cancer group and 1?321 in control group. The sensitivity (0.798?7) and specificity (0.934?1) was obtained by Fleiss model. Conclusion The meta-analysis shows that telomerase is a rather novel diagnostic tumor marker. These results will provide theoretical basis for bringing telomerase activity detection into lung cancer screening plan.